

Yuliya Petrova-Lumer Linhares, M.D.
MCI Baptist Health Chief of Lymphoma Services
Florida International University Associate Professor, Translational Medicine

CURRICULUM VITAE

Rev. 03.27.2025

PROFESSIONAL CONTACT INFORMATION

Business Address Miami Cancer Institute, Memorial Sloan Kettering Cancer Alliance member
Blood and Marrow Transplant Program
8900 N. Kendall DR
Miami, FL 33176
Tel 310-795-6849
Email: yuliyal@baptisthealth.net
Personal: yuliyalin@gmail.com

EDUCATION

8/1998-5/2000 Bachelor of Science Biology, *Magna Cum Laude*
Lenoir-Rhyne University, Hickory, NC

8/2000- 5/2006 Doctor of Medicine *with Distinction*
UNC Chapel Hill School of Medicine, Chapel Hill, NC

7/2006-6/2007 Internship, Department of Internal Medicine
University of California in Los Angeles

7/2007-6/2009 Residency, Department of Internal Medicine
University of California in Los Angeles

7/2009-6/2012 Fellowship in Hematology-Oncology
Department of Internal Medicine
University of California in Los Angeles

9/2012- 5/2013 Cedars-Sinai Clinical Scholars Program;
Biomathematics 170A Medical Statistics with Jeff Gornbein

PROFESSIONAL EXPERIENCE:

8/2019 – Present Chief of Lymphoma Service, Miami Cancer Institute,
Florida International University Associate Professor, Translational
Medicine

8/2012 – 6/2019	Staff Physician I, Blood and Marrow Transplant Program Cedars-Sinai Medical Center, Los Angeles, CA
5/2018- 6/2019	Chimeric Antigen Receptor Therapies Clinical Director, Cedars-Sinai Hospital, Los Angeles, CA
8/2013 – 6/2019	Assistant Professor of Medicine, Division of Hematology/Oncology Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
8/2013- 6/2019	Health Sciences Assistant Clinical Profesor Division of Hematology/Oncology Department of Medicine, UCLA School of Medicine, Los Angeles, CA

Previous Non- Physician Positions:

1996 – 1998	English-Russian Interpreter, Intourist, Museum and City Tour Guide Saint-Petersburg, Russia
2001-2003	English-Spanish interpreter Student Health Action Coalition (SHAC) Clinic Chapel Hill, NC
2003 – 2005	Research Scholar NIH-HIDCR/Howard Hughes Medical Institute (HHMI) Bethesda, Maryland

MEDICAL LICENSE

Florida Department of Health ME140422

BOARD CERTIFICATIONS

Date: 8/27/2009	Internal Medicine, Certificate Number: 299127, renewed 2021
Date: 10/25/2012	Hematology- renewed via 10-year assessment 4/2023
Date: 10/25/2013	Oncology, maintained via continuous assessment program
Date: 10/31/2021	Lifestyle Medicine, American Board of Lifestyle Medicine diplomate

PROFESSIONAL ACTIVITIES:

2019- ongoing: Established Multidisciplinary Cutaneous Lymphoma Program at Miami Cancer Institute [Cutaneous Lymphoma | Expert Diagnosis & Treatment | Miami Cancer Institute \(baptisthealth.net\)](#)

2019-ongoing: Lymphoma Tumor Board, Lymphoma Pathways and SOP development,

implementation of novel regimens, CARTs at Miami Cancer Institute (est 2017)- US News and World Report 2023 Miami Cancer Institute Named “high performing” in leukemia, myeloma, and lymphoma (top 10% within the specialty)

Professional Memberships:

Cedars-Sinai Medical Center

8/2012- 6/2019	Member, Samuel Oschin Comprehensive Cancer Institute
8/2012 - 6/2019	Member, Bone Marrow Transplant Disease Research Group
8/2014 – 6/2019	Member, Leukemia Disease Research Group
8/2014 – 6/2019	Member, Bone Marrow Transplant Standard Operating Procedure Multidisciplinary Team

Other Professional Memberships/Associations:

2012- Present	American Society of Hematology
2013- Present	American Society for Blood and Marrow Transplantation
2022- Present	International Society for Cutaneous Lymphomas
2022- Present	United States Cutaneous Lymphoma Consortium

Committee Service:

2019- Present	Scientific Protocol Review Committee Miami Cancer Institute
2019- Present	P & T Committee Miami Cancer Institute

Editorial Services:

2015 - Present	Reviewer for the “ <i>Clinical Transplantation</i> ” Journal
2016 - Present	Reviewer for “ <i>Experimental Hematology</i> ” Journal

Consulting Services:

2010 – 2012	Consultant, Partnership for Health Analytic Research, LLC
-------------	---

Community Service:

2012 – Present	Participant/Fundraiser, Be The Match Marrow Registry Fundraising
----------------	--

HONORS AND SPECIAL AWARDS

2000	North Carolina Academy of Sciences Derieux Award - award for the best undergraduate medical research
2002	John B. Graham Research Society Award, UNC School of Medicine
2002	Alpha Omega Alpha
2003	MEDWorld (Medical Equipment for the Developing World) Most Valuable Volunteer Award
2003- 2004	Howard Hughes Medical Institute Research Fellowship at NIH
2004- 2005	Howard Hughes Medical Institute Continued NIH Research Fellowship
5/14/2006	MD with Distinction
2006 – 2007	Commendation for Excellence in Medical Student Teaching

2008 – 2009

Commendation for Excellence in Medical Student Teaching

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:

- 1.) **Howard Hughes Medical Institute Research Fellowship at NIH**, Research Scholar training Fund. Yuliya Linhares, Co-Investigator; 8/30/2003-8/30/2004, **\$24,000.**
- 2.) **California Institute of Regenerative Medicine**, Clinical Fellow Training Fund. Yuliya Linhares, Co-investigator; 7/1/2010-6/30/2011, **\$97,000.**
- 3.) Miami Cancer Institute Foundation Grant **\$ 56,400.00** to fund the correlative laboratory studies for the IIT **Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-In**
- 4.) BeiGene Pharmaceuticals drug and funding for IIT **Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-In \$312,558.66 USD**
- 5.) Swim Across America – Grant for the LIN001 IIT, fundraising in progress

RESEARCH EXPERIENCE:

Principal Investigator MCI:

- 1) **BMS: USON 18104: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)- 1 st author and presenter on 2 ASH abstracts and SOHO abstract, corresponding author on Blood Advances publication**
- 2) **BMS: Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T cells (TRANSCEND-OUTREACH-017007)**
- 3) **Seattle Genetics: SGN35-027 Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subject- co-author on 2 ASH 2022, 2023, 2024 as well as co-author on the manuscript in the process of submission to JCO**
- 4) **ADC Therapeutics: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)**
- 5) **Miltenyi Biomedicine: Title: A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma 3 patients accrued**
- 6) **ADC Therapeutics: Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma (LOTIS-5) ASCO 2022 Poster Abstract, presenter**

- 7) **F. Hoffmann-La Roche** Phase III, Multicenter, Randomized, Open-label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B Cell Lymphoma (SkyGlo)
- 8) **Allogene:** A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)
- 9) **Verastem:** MSKCC 18-377: Multi- Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL).
- 10) **ATARA** Single patient IND Tabelecleucel for the treatment of refractory AITL with concurrent high grade EBV viremia

Principal Investigator MCI – Investigator-Initiated Trials:

- 1.) LIN001: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-In **ASH 2022 Abstract**
- 2.) 2022-RETRO-LIN-001: Real World Experience of Polatuzumab Containing Regimen in the Second Line for Lymphoma **ASH 2022 Poster Abstract, manuscript in progress**
- 3.) 2022-RETRO-LIN-002: Prevalence of Medical Conditions Treatable and Preventable with Lifestyle Modifications in Miami Cancer Institute Malignant Hematology Clinic: A Pilot Retrospective Record Review with the Goal of Developing and Implementing an Interventional Multidisciplinary Lifestyle Modification Plan in Oncology Clinic **LSMC 2022 Poster Abstract**
- 4.) 2022-RETRO-LIN-003 Real World Experience of the use of a FLU-TBI conditioning regimen in the setting of allogeneic stem cell transplantation for hematologic malignancies **EBMT Poster Abstract 2023**
- 5.) 2023-RETRO-LIN-004: Rituximab Lenalidomide Ibrutinib in Patients with Relapsed-Refractory Primary and Secondary CNS Lymphoma: **Blood supplement ASH ABSTRACT 2023**

Principal Investigator and Co-Principal Investigator Cedars-Sinai Medical Center:

- 1.) **Juno 017007:** A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting 5%

- 1.) **Juno 017006:** Phase 2 Study of Lisocabtagene Maraleucel as Second-Line therapy in adult patients with aggressive B-cell NHL (017006) 5% effort
- 2.) **eFT508-0002:** A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies. PI: Y. Linhares. \$22,000. 2018-present. (1% Effort)
- 3.) **Hybrigenetics ICT-8:** Phase 2, Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy.
- 4.) **Novartis Single Patient IND (135342):** Individual Use of Ruxolitinib for Chronic Graft-Versus-Host Disease
- 5.) **DRBEAT PRO00019873:** A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma. PI: Y. Linhares. \$300,000. 2010-2018 (10% Effort)
- 6.) **Bristol Myers-224334 CA209-205 PRO00036844:** Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab in Classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT). PI: Y. Linhares. \$160,000 11/11/2014-2017 (7.8% Effort)
- 7.) **Genentech Inc. – 221664 PRO00030492 GO27834:** A Randomized, Open-Label, Multicenter, Phase II trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. PI: Y. Linhares. \$1, 579,804. 8/17/2012-5/29/18. (14.50% Effort)
- 8.) **Pharmacyclics-223766 PRO000394901 PCYC-1123-CA:** A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. PI: Y. Linhares. \$73,125. 3/10/2014-9/9/16 (5.60% Effort)
- 9.) **Kyowa Hakko Kirin Pharma-221227 0761-009 KYOWA PRO00028793:** Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 versus Investigator's Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL). PI: M. Lill. \$163,145. 8/14/2012-5/3/18 (6.9% Effort)
- 10.) **Onyx-223176 PRO00033794 2012-002:** A Phase 1/2 Study of Weekly Carfilzomib in Combination with Dexamethasone in Progressive Multiple Myeloma. PI: M. Lill. \$191,648. 2/25/2014-1/10/18 (5.0% Effort)

- 11.) **Gamida Cell Ltd. – 224571 GC0301020 PRO00037199:** Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients with Hematological Malignancies (Phase I/II study). (6.10% Effort) \$ 100,000. 11/9/2014- 9/29/2016.
- 12.) **ASTX660-01: A Phase 1-2 Study of a Drug ASTX660 in Patients with Advanced Solid Tumors and Lymphomas:** lead Co-PI for the lymphoma cohort; (2% Effort)
- 13.) **FORMA 1101-HEM-101:** A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed or Refractory Hematologic Malignancies.
- 14.) **IIT Merin IIT2017-03- HaploBFR:** Bendamustine, fludarabine, and rituximab conditioning for haploidentical stem cell transplantation for relapsed/refractory lymphoma, multiple myeloma, and CLL.
- 15.) **Janssen R&D LLC 222105 FLR2002:** An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma. Co-PI: Y. Linhares. \$110, 202. 6/3/2013-10/21/16 (4.1% Effort)
- 16.) **Janssen Research & Dev.LLC-221324 PCI-32765 MCL2001 PRO00031627:** A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy. PI: M. Lill. \$96,000. 8/17/2012-10/21/16. (3% Effort) 6 patients consented.

INVITED LECTURES AND PRESENTATIONS:

1. 4/11/2025 Ocean Reef Young Presidents of America “How to Improve Your Health without Medications”
2. 3/2025 Ocean Reef Community Presentation “Brain Power”
3. 2/2025 Ocean Reef Community Presentation “From my heart to your gut: let's beat cancer (and other diseases) before they even start”
4. **Cutaneous Lymphoma Foundation Spanish Patient Education Forum “Cutaneous Lymphoma Staging and Treatments for Advanced Disease” 01/2025**
5. **Baptist Founder Retreat, Baptist Main, Miami- Improve your health without medications-take control of your epigenetics and microbiome, 9/2024**
6. **Rehabilitation Medicine Conference, Baptist Health South Florida, Miami- Lifestyle Changes to Prevent and Improve Cancer Outcomes 10/19/2024**
7. **ESMO South Florida, Faurt Lauderdale- Lymphoma Updates 10/26/2024**
8. **Duke University Malignant Hematology Grand Rounds- “Primary CNS Lymphoma” 3/2024**
9. **Community Cases in Oncology Tampa – Total Health Conferencing “Novel therapies for**

DLBCL” 8/2023

10. **VuMedi** Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study Linhares et al 3/2023
11. **VuMedi** Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Linhares et al. 3/2023
12. **University of Miami Oncology Grand Rounds:** Post-Transplant Cytosan as GvHD Prophylaxis Platform Across Donor Types, Conditioning Regimens, Age, and Hematologic Malignancies 11/20/2020
13. **MCI International Department** lecture for the international physicians and medical students. Novel Treatments for Lymphoma: Focus on Targeted Therapies 4/14/2021
14. **VuMedi** Immunotherapy in Relapsed/Refractory Hodgkin Lymphoma: How to Choose and When? 5/2022
15. **Curio Science:** Hodgkin Lymphoma Workshops (Miami, Denver, New Orleans, Birmingham) 2022
16. **ESMO highlights-** “How We Treat Early Lymphoma Relapse” 10/9/2022
17. **ASCO/ESMO Highlights-** “Updates in T-cell Lymphomas” 10/15/2022
18. **Cayman Islands Health Conference** “Optimizing Your Health Without Medications: Gain Control of Your Microbiome and Epigenetics through Lifestyle Modifications” 10/21/2022
19. **Los Angeles Lymphoma Rounds** “Follicular Lymphoma in an Older Patient”, April 2019
20. **Pulmonary and Critical Care Grand Rounds**, Cedars-Sinai, Los Angeles, “CART Toxicity Management” March 2019
21. **Los Angeles Lymphoma Rounds** “Relapsed AITL and Refractory PMBCL”, February 2018
22. **Alexion Pharmaceuticals** “Thrombotic Microangiopathies”, Laguna Beach, October 2015
23. **Gamida Cell** “Bone Marrow Transplant Overview”, New York, October 2014
24. **VuMedi OUTREACH** Liso-Cel trial presentation recording 5/9/2025

- 1.) 10/17/2019 Light the Night Bentley Miami Meeting and Reception
- 2.) 11/02/2019 Light the Night Leukemia and Lymphoma Society Event
- 3.) 11/2019 Round Table with the Elders of Jehovah's Witness Community
- 4.) 2/29/2020 Leukemia and Lymphoma Society Blood Cancer Conference: Multiple Myeloma Breakout Session "Multiple Myeloma Treatment Overview" (1 hr lecture)
- 5.) 6/16/2020 on-line Zoom lecture for the patients and physicians via Leukemia and Lymphoma Society: Non-Hodgkin's Lymphomas Biology and Treatment (community event) (1 hr lecture)
- 6.) 10/21/2020 Interview for the CURE (Cancer Updates Research and Education) publication: "What Should Mycosis Fungoides Patients Know about their Diagnosis and Treatment."
- 7.) 11/19/2020 Light the Night virtual event
- 8.) 1/20/2020 Leukemia and Lymphoma Society "ABC's of Blood Cancer-Decode What Your Doctor is Saying" in collaboration with MSK, moderator Dr. Matthew Matazar
- 9.) 2/17/2021 Guatelevision interview regarding the general information on lymphomas and leukemias
- 10.) 2/23/2023 HealthTree Lymphoma and DLBCL Basics for Patients – Recorded Interview
- 11.) 7/13/2023 Voices of CTCL -Cutaneous Lymphoma – responsibility to the People of Color Project
- 12.) 7/13/23- SEEK Conference CTCL in POC
- 13.) 4/2024 Ocean Reef Community Presentation "How to Improve Your Health Without Medications"
- 14.) 4/12/2025 Swim Across America CNS Lymphoma Trial Overview

TEACHING:

2012- 2019 Cedars-Sinai resident and fellow teaching evaluations consistently "excellent"

Clinical Teaching:

- 1.) June 12, 2018: Hematology Oncology Fellow Journal Club: Mantle Cell Lymphoma Treatment
 - 2.) 4/2016- ongoing Cedars-Sinai Hospital: preceptorship for the clinic rotations for Medical Sciences PhD students, PharmD students, residents and fellows
 - 3.) 2021- ongoing: Miami Cancer Institute preceptorship and didactic teaching for rotating FIU medical students, PharmD candidates, residents and fellows
 - 4.) 2012-2021 Cedars-Sinai Hospital: weekly, didactic teaching on bone marrow transplant ward and hematology-oncology consult service
-
- 1.) 11/2011 International Society for Pharmacoeconomics and Outcomes Research European Congress Systematic Review of Skeletal Related Events in Breast Cancer Systematic Review of Skeletal Related Events in Prostate Cancer
 - 2.) 04/2012 "T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics." ACC Conference

- 3.) 10/16/2012 “Acute Myeloid Leukemia: Beyond 7 + 3” Cedars-Sinai Medical Center, Hematology/Oncology Grand Rounds
- 4.) 11/13/2012 Catastrophic Antiphospholipid Syndrome, Cedars-Sinai Medical Center, Internal Medicine Residency Program Morning Report
- 5.) 12/ 4/ 2012 Thymoma Versus Sclerosing Mediastinitis, Tumor Board Presentation, Cedars-Sinai Medical Center
- 6.) 12/19/ 2012 3rd year UCLA Medical Student Case Based Seminar: Lymphoma, Leukemia
- 7.) 9/19/2013 3rd year UCLA Medical Student Case Based Seminar: Anemia
- 8.) 12/2013 Thrombosis and Thrombophilia, Cedars-Sinai Internal Medicine Resident Lecture Series
- 9.) 12/17/2013 Acute Leukemia’s, Resident Lecture Series (1hr lecture)
- 10.) 2013 –Present: developed multiple lectures on various hematology topics including acute and chronic leukemias, lymphomas, thrombotic microangiopathy, anemia, hypercoagulable disorders, basics of bone marrow transplant. Lectures are in Power Point format, available to the residents at: www.dropbox.com
- 11.) 3/18/2014 “Highlights of ASBMT Cedars-Sinai Hematology/Oncology Grand Rounds
- 12.) 5/20/14 Acute Myeloid Leukemia, Basics of Stem Cell Transplant, Hematologic Malignancies resident ward lecture series
- 13.) 8/13/2014 “NK/T Cell Lymphoma” SOCCI Multi-Disciplinary Tumor Board
- 14.) 12/10/2014 “PLTD,” SOCCI Multi-Disciplinary Tumor Board
- 15.) 12/15/2014 3rd year UCLA Medical Student Case Based Seminar: “Oncologic Emergencies”
- 16.) 4/28/2015 Hem-Onc Fellows Journal Club “Treatment of Acute Lymphoblastic Leukemia”
- 17.) 4/2015 “NK/T Cell Leukemia with HLH” SOCCI Multi-Disciplinary Tumor Board
- 18.) 7/2015 “Thrombotic Microangiopathies” Resident Morning Report
- 19.) 8/2015 Lymphomas, Acute Leukemias Residents Lectures
- 20.) 9/22/2015 Hem-Onc Fellow Journal Club “Thrombotic Microangiopathies”
- 21.) 9/30/2015 “Hematologic Emergencies” Resident Lecture
- 22.) 7/6/2016 Anesthesiology Grand Rounds “Hematologic Emergencies”

- 23.) 8/2018 planned “Hematologic Emergencies” Resident Lecture
- 24.) 5/22/2018 “CARTs: Design, Clinical Applications and Future Directions” Cedars-Sinai Hematology/Oncology Grand Rounds
- 25.) 9/6/2017 Medical student seminar “Oncologic Emergencies”
- 26.) 6/2017 Medical student seminar on hematologic malignancies
- 27.) 6/2017 Resident noon lecture “Hematologic Emergencies”
- 28.) 4/12/2017 “Rare Lymphomas,” SOCCI Multi-Disciplinary Tumor Board
- 29.) 1/12/17 Medical Student Seminar “Leukemias and Lymphomas”
- 30.) 2/28/18, 8/17/18, 2/20/19, 4/19/19 Medical Student Seminar “Oncologic Emergencies”
- 31.) 9/25/2019 Pulmonary complications of Bone Marrow Transplant
- 32.) 10/23/2019 Bone Marrow Transplant Emergencies, lecture for the Pulmonary and Critical Care APPs
- 33.) 6/17/2020 APP lecture: CART Biology, Clinical Trial Overview and Toxicity Management
- 34.) 7/15/2020 General Lecture: CART Biology, Clinical Trial Overview, Focus on Toxicity Management
- 35.) 3/2023 Texas A&M School of Medicine Lecture “How to Improve Your Health without Medications- Practical Approach”
- 36.) 4/10/2025 Baptist Physical Therapy Department Educational Lecture “How to Improve Your Health without Medications”
- 37.) 6/5/2025 FIU Family Medicine Residency Lecture “How to Improve Your Health without Medications”
- 38.) 5/29/2025 APP Lifestyle Medicine Lecture

MEDIA APPEARANCES:

BBC documentary: Louis Theroux’s LA Stories TV Miniseries “Edge of Life” 2014

The Goop Lab Netflix on The Wim Hof Method and Cold Therapy 2019

Guatemala TV News Episode on Blood Cancers 2021

PBS South Florida “Hope Is Here” episode 2023

Cutaneous Lymphoma Foundation Patient Journeys 2023

PUBLICATIONS/BIBLIOGRAPHIES:

A.) Research Papers- Peer-Reviewed:

- 1.) Atsuko Sakurai, Julie Gavard, **Yuliya Annas-Linhares**, John R. Basile , Panomwat Amornphimoltham, Todd R. Palmby, Hiroshi Yagi, Fan Zhang, Paul A. Randazzo, Xuri Li , Roberto Weigert, and J. Silvio Gutkind “Semaphorin 3E initiates anti-angiogenic signaling through Plexin-D1 by regulating Arf6 and R-Ras” *Molecular Cell Biology* 2010, Apr 12
- 2.) Ling Cao, William Dean Wallace, Shahrooz Eshaghian, **Yuliya Linhares**, Victor J. Marder, Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH), *International journal of Hematology*, Sep 2011
- 3.) Broder MS, Gutierrez B, Cherepanov D, **Linhares Y.** Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. *Support Care Cancer*. 2015 Jan;23(1):237-47
- 4.) Qin Huang, Alia Nazarullah, Michelle Don, **Yuliya Linhares**, Serhan Alkan, Aggressive NK-cell Leukemia: A rare entity with diagnostic and therapeutic challenge, *Human Pathology: Case Reports*. Aug 2015
- 5.) Joel Epstein, DMD, MSD; Judith Raber-Durlacher; Michael Lill; **Yuliya Linhares**; Andrei Barasch; Romee Slief; Margot Geuke; Judith Zecka; Dan Milstein; Dimitrios Tzachanis Photobiomodulation therapy in the management of chronic oral graft-versus-host disease. *Supportive Care in Cancer* Apr 2016
- 6.) Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, **Linhares Y**, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. *Br J Haematol*. 2017 Aug 2. doi: 10.1111/bjh.14879.
- 7.) Gastrointestinal Transplant-Associated Thrombotic Microangiopathy: A Case Report and Literature Review Wirtschafter, E., VanBeek, C. & **Linhares, Y.** *Exp Hematol Oncol* (2018) 7: 14. <https://doi.org/10.1186/s40164-018-0106-9>
- 8.) Beck, A., Lin, R., Reza Rejali, A., Rubens, M., Paquette, R., Vescio, R., Merin, N., Guerrero, M., Federizo, Y., Lua, M., Uy, L., Hernandez, L., Allred, M., Legaspi, R., Leaverton, M., Oliva, S., Castillo, R., Dean, L., Bourke, J., Cooper, S., ... **Linhares, Y. P.** (2020). Safety of

bloodless autologous stem cell transplantation in Jehovah's Witness patients. *Bone marrow transplantation*, 55(6), 1059–1067. <https://doi.org/10.1038/s41409-019-0777-9>

- 9.) Ramamoorthy, V., Rubens, M., Saxena, A., Bhatt, C., Das, S., Appunni, S., Veledar, E., McGranaghan, P., Shehadeh, N., Viamonte-Ros, A., **Linhares, Y.**, Odia, Y., Kotecha, R., & Mehta, M. P. (2020). Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States. *The American journal of hospice & palliative care*, 1049909120928980. Advance online publication. <https://doi.org/10.1177/1049909120928980>
- 10.) Rubens, M., Ramamoorthy, V., Saxena, A., Das, S., Bhatt, C., Veledar, E., McGranaghan, P., Sundil, S., Shehadeh, N., Viamonte-Ros, A., **Linhares, Y.**, Odia, Y., Chuong, M., Kotecha, R., & Mehta, M. P. (2020). Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016. *American journal of clinical oncology*, 43(5), 349–355. <https://doi.org/10.1097/COC.0000000000000670>
- 11.) Brothers J, Castillo DR, Jeon WJ, Joung B, **Linhares Y**. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia. *Hematology*. 2023 Dec;28(1):2237342. doi: 10.1080/16078454.2023.2237342. PMID: 3748597
- 12.) A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Linhares et al. *Blood Advances August 2024*
- 13.) Fattah YH, Crasto D, Liu SS, **Linhares Y**, Kerdel F, Hanly A, Karai LJ. DUSP22-IRF4 Rearranged CD30-Positive Primary Cutaneous Lymphoproliferative Disorder With Gamma/Delta Phenotype. *Am J Dermatopathol*. 2023 Oct 26. doi: 10.1097/DAD.0000000000002573. Epub ahead of print. PMID: 37883980.
- 14.) Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. *Blood*. 2025;145(3):290-299. doi:10.1182/blood.2024024681
- 15.) N. Merin, Linhares Y et al "Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Transplantation: Retrospective Analysis at a Single Center" (reference number: BMT-2024-1110), ***submitted to Bone Marrow Transplantation.***

Reviews:

- 1.) **YPL Linhares**, S Pavletic and RP Gale Chronic GVHD: Where are we? Where do we want to be? Will IMiDs help? *Bone Marrow Transplantation* (2013) 48, 203–209
- 2.) Zeidan AM, **Linhares Y**, Gore SD Current Therapy of Myelodysplastic Syndromes. *Blood Rev*. 2013 Sep; 27(5):243-59

- 3.) Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. Tabatabai R, **Linhares Y**, Bolos D, Mita M, Mita A, Target Oncol. 2017 Jun 26. Doi: 10.1007/s11523-017-0507-4.
- 4.) **Linhares Y**, Kaganski A, Agyare C, Kurnaz IA, Neergheen V, Kolodziejczyk B, Kędra M, Wahajuddin M, El-Youssfi L, Dela Cruz TE, Baran Y, Pešić M, Shrestha U, Bakiu R, Allard PM, Rybtsov S, Pieri M, Siciliano V, Flores Bueso Y. Biodiversity: the overlooked source of human health. Trends Mol Med. 2023 Mar;29(3):173-187. doi: 10.1016/j.molmed.2022.12.002. Epub 2022 Dec 28. PMID: 36585352.
- 5.) A. Perez Perez, G Nahas, T. Al Sagheer, Y Linhares "Outpatient Administration of CAR T-Cell Therapy: A Focused Review with Recommendations for Implementation in Community Based Centers" has been approved for production and accepted for publication in Frontiers in Immunology May 2024
- 6.) Michel Wakim, Mariana Mezher MD, MD, Tiba Al Sagheer, Pharm D, Ariel Perez-Perez, MD, George Nahas, MD, **Yuliya Linhares, MD** Novel Therapies in Primary Central Nervous System Lymphoma *under review with Clinical Pharmacology: Advances and Applications 11/2024*

Conference Abstracts:

- 1.) **Linhares Y**, Gavard J, Basile JR, Gutkind JS Semaphorin 3E/plexin-D1 Signaling Induces Focal Adhesion Disassembly, Inactivates Rho and Inhibits Endothelial Cell Motility, AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications., Publication Date: 11 / 2005
- 2.) Broder M, Gutierrez B, **Linhares Y** Systematic Review of Skeletal Related Events in Prostate Cancer Value in Health Volume 14, Issue 7 pA437 Nov 2011
- 3.) Broder M, Gutierrez B, **Linhares Y** Systematic Review of Skeletal Related Events in Breast Cancer Value in Health Volume 14, Issue 7 pA437 Nov 2011
- 4.) Pharmacologic Doses of Amiloride Preferentially Induce Apoptosis and Growth Inhibition of Flt3-ITD Mutation Positive Acute Myeloid Leukemia Cell Lines **Yuliya Linhares**, Jade Dardine and Siavash Kurdistan Blood 2011 118:5004
- 5.) Starshak P, **Linhares Y**, Rao PN Multidisciplinary Approach in the Diagnosis of T-PLL, Cytogenetics and Genome Research Volume 136 Issue 4 p354-455 Abstract 79 2012
- 6.) Yatawara, M Van Strien P, Dudley, K, Huang, SC, Abess L, Guerrero M, Snoussi L, Caso C, Gharapetian S, Uy L, Delioukina M, **Linhares Y**, Lill M, Lim S Transplant Information Patient System (TIPS): Development of a Web-Based Bone Marrow Transplant Workflow Tool, Providing Transplant Process Automation and Efficiency ; Biology of Blood and Marrow Transplantation. Vol 20, Issue 2, pS95-96 Meeting Abstract 111 Feb 2014
- 7.) Beck A. Lin R. **Linhares Y**. Rejali A. et al. Safety of Bloodless Autologous Stem Cell Transplantation in Jehovah's Witness Patients TCT Meeting Poster Feb 2020

- 8.) **Yuliya Linhares**, Mitul Gandhi, Michael Chung, Jennifer Adeleye, David Ungar, Mehdi Hamadani, Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma. Publication Number: 2107 Submission ID: 136614 62nd ASH Annual Meeting and Exposition. Session Name: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials

- 9.) Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, **Yuliya Linhares**, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak; Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B). *Blood* 2021; 138 (Supplement 1): 2454.

- 10.) Phase 3 Randomized Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) Versus Immunochemotherapy in Patients with R/R DLBCL (LOTIS-5) Mehdi Hamadani, **Yuliya Linhares**, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella, Ed Kingsley, Julien Depaus, Sylvia Snauwaert, Michal Kwiatek, Javier López-Jiménez **PRESENTER** ASCO Meeting June 4 2022

- 11.) **EHA 2022** Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL (LOTIS-5) Mehdi Hamadani, **Yuliya Linhares**, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella, Ed Kingsley, Julien Depaus, Sylvia Snauwaert, Michal Kwiatek, Javier López-Jiménez

- 12.) **EHA 2022 BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY RESULTS FROM THE SINGLE-ARM PHASE 2 STUDY (SGN35-027 PART B)** Lee, H.; Flinn, I. W.; Melear, J; Ramchandren, R. Friedman, J. Burke, J. M. **Linhares, Y.**; Raval, M; Chintapatla, R. Feldman, T. A.Yimer, H. Islas-Ohlmayer, M. Dean, A. Rana, V.Gandhi, M. D.Renshaw, J.Gillespie-Twardy, A. L. Ho, L. Puhlmann, M.Guo, W.Yasenchak, C. A.

- 13.) **ASH Annual Meeting 2022**; New Orleans, LA Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: Updated efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part B) Hun Ju Lee¹, Ian W. Flinn², Jason Melear³, Rod Ramchandren⁴, Judah Friedman⁵, John M. Burke³, **Yuliya Linhares³**, Paul Gonzales⁶, Mihir Raval³, Rangaswamy Chintapatla⁷, Tatyana A. Feldman⁸, Habte Yimer³, Miguel Islas-Ohlmayer^{3,9}, Asad Dean³, Vishal Rana¹⁰, Mitul D. Gandhi³, John Renshaw³, Linda Ho¹¹, Michelle A. Fanale¹¹, Wenchuan Guo¹¹, Christopher A. Yasenchak¹²

- 14.) **ASH Annual Meeting 2022**; New Orleans, LA Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C) Hun Ju Lee¹, Jeremy S. Abramson², Nancy Bartlett³, John M. Burke⁴, Ryan Lynch⁵, Eva Domingo Domench⁶, Brian Hess⁷, Steven Schuster⁸, **Yuliya Linhares⁹**, Rod Ramchandren¹⁰, Mitul Gandhi¹¹, Rex Mowat¹², Harsh Shah¹³, Giuseppe Rossi¹⁴, Uwe Hahn¹⁵, Miles Prince¹⁶, Linda Ho¹⁷, Wenchuan Guo¹⁷, Christopher A. Yasenchak¹⁸, David Straus¹⁹
- 15.) **Lifestyle Medicine Conference November 2022, Orlando, Florida** Malignant Hematology Clinic as a Platform for Lifestyle Medicine Interventions: Rational and Plan of Intervention Poster Abstract Shreya Sachdeeva, Tiba Al Sagheer, Ariel Perez Perez **Yuliya Linhares**
- 16.) **ASH Annual Meeting 2022**; New Orleans, LA OUTREACH abs (BRPULCL2236a) Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) **Linhares et al.**
- 17.) **ASH Annual Meeting 2022**; New Orleans, LA BRPULCL2237a (ASH OUTREACH PRO abs) Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study **Linhares et al .**
- 18.) **ASH Annual Meeting 2022; New Orleans, Polatuzumab- Rituximab with or without Bendamustine As Second-Line Therapy for Relapsed Refractory Large B-Cell Lymphomas: Single Center Experience** Ariel Perez Perez,, Shreya Saxena,Tiba Al Sagheer, Muni Rubens, Talia Zahra, George Nahas, Alex V. Mejia Garcia, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Atulya Khosla, Manmeet Ahluwalia, Guenther Koehne, **Yuliya P.L. Linhares**
- 19.) **ASH Annual Meeting 2022 Blood (2022)** 140 (Supplement 1): 12061–12063 Trial In Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas, A Phase II Trial with a Safety Lead-in **Yuliya Linhares**, Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Alex Mejia-Garcia, Muni Rubens, Talia Zahra, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Yazmin Odia, Guenther Koehne
- 20.) **Lifestyle Medicine Conference Orlando 10/2023 Pilot Study to introduce Lifestyle modifications for better outcomes in the Malignant Hematology Clinic at Miami Cancer Institute** Tiba AlSagheer, Pharm D, Shreya Saxena, Ariel Perez-Perez, MD, Yuliya Linhares, MD
- 21.) **EBMT Paris 2023: The FLU-TBI myeloablative conditioning regimen is associated with favorable outcomes in mismatched and haploidentical allogeneic transplantation in adult**

patients with ALL treated with contemporary regimens Nadia Bambace, Ariel Perez Perez, Tiba Al Sagheer , Talia Zahra, Muni B. Rubens , Guenther Koehne, **Yuliya P.L. Linhares**

- 22.) **EHA 2023: Title: Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: updated efficacy and safety results from the single arm phase 2 study** Yasenchak, Christopher A.; Flinn, Ian W. Melear, Jason Ramchandren, Rod Friedman, Judah Burke, John M. **Linhares**, **Yuliya** Gonzales, Paul Raval, Mihir Chintapatla, Rangaswamy Feldman, Tatyana A.Yimer, Habte Islas-Ohlmayer, Miguel Dean, Asad; Rana, Vishal; Gandhi, Mital D.; Renshaw, John; Ho, Linda Fanale, Michelle A.; Guo, Wenchuan; Lee, Hun Ju
- 23.) **17th ICML Meeting; June 13-17, 2023; Lugano, Switzerland Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Early-Stage Classical Hodgkin Lymphoma: Updated Results From an Ongoing Phase 2 Study (SGN35-027 Part C)** J. S. Abramson- D. Straus N. L. Bartlett J. M. Burke R. C. Lynch E. Domingo-Domenech B. Hess S. Schuster **Y. Linhares** R. Ramchandren, M. Gandhi R. Mowat H. Shah, W. Jurczak A. Re U. Hahn H. M. Prince, W. Guo, L. Ho S. Jain¹ C. A. Yasenchak, H. J. Lee
- 24.) **2023 Society of Hematologic Oncology - 11th Annual Live Meeting in Houston, Texas** “Primary results from OUTREACH: a phase 2 study of lisocabtagene maraleucel (liso-cel) administered in the community setting as outpatient or inpatient treatment in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)” **Yuliya Linhares et al. presenter**
- 25.) **ASH 2023 Oral Presentation Classical Hodgkin Lymphoma: Updated Results Reporting Progression-Free Survival in an Ongoing Phase 2 Study (SGN35-027 Part C)** Jeremy S. Abramson, David Straus, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Eva Domingo-Domenech, Brian Hess, Steven Schuster, **Yuliya Linhares**, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Wojcieh Jurczak, Alessandro Re, Uwe Hahn, H. Miles Prince, Wenchuan Guo, Linda Ho, Rose Beck, Christopher A. Yasenchak, Hun Ju Lee
- 26.) **ASH 2023 Oral Presentation Title: Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study (SGN35-027 Part B)** Jeremy S. Abramson, David Straus, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Eva Domingo-Domenech Brian Hess, Steven Schuster, **Yuliya Linhares**, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Wojcieh Jurczak, Alessandro Re, Uwe Hahn, H. Miles Prince, Wenchuan Guo, Linda Ho, Rose Beck, Christopher A. Yasenchak, Hun Ju Lee
- 27.) **ASH 2023 Blood abstract TITLE: Rituximab Ibrutinib Lenalidomide (R2I) Combination for Primary or Secondary Large B-Cell CNS Lymphoma: Last Resort or Bridge to Cellular Therapy?** A. Perez Perez T AlSagheer. **Y Linhares**
- 28.) **Panpacific Lymphoma Conference 7/2024 Title: Comparative Analysis of Lumbar Puncture Utility in Diagnosis of Primary versus Secondary CNS Lymphoma: A Retrospective Study** Amina Namrouti, Mainak Bardhan, Tiba Al Sagheer, **Yuliya Linhares**, Yazmin Odia, Manmeet S Ahluwalia, Zhijian Chen

- 29.) **J Abramson et al ASH 2024 Oral Presentation Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma**
- 30.) **A. Perez Perez et al ASH 2024 Poster presentation** Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
- 31.) **ASCO 2025 Efficacy of Pemetrexed-Based Regimens in Primary CNS Lymphomas: A Single-Center Retrospective Analysis** Tarlan Kehtari¹ Raghuram Reddy ¹ Ariel Perez Perez ^{1, 2} Yazmin Odia ^{1, 2} Tiba Alsagheer² Manmeet Ahluwalia ^{1, 2} Zhijian Chen ^{1, 2} George Nahas ^{1, 2} Muni Rubens ² Yuliya Linhares ^{1, 2}
- 32.) **ASCO 2025** Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab
- 33.) **ASCO 2025** “ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy”
- 34.) EHA 2025 EHA-1584 Pemetrexed and zanubrutinib combination in R/R CNS B-cell lymphoma: preliminary report of the safety lead-in cohort in a single center phase II study Type: Poster Presentation Yuliya Linhares ^{1, 2} Tiba Alsagheer¹ Ariel Perez Perez ^{1, 2} Yazmin Odia ^{1, 2} Zhijian Chen ^{1, 2} Manmeet Ahluwalia ^{1, 2} Amy Starosciak ¹ Claudia Torralbas ¹ Maria Abreu ¹ Julia Steger² Jeremy Purow² Guenther Koehne ¹,
- 35.) EHA 2025 EHA-2747 Efficacy of Pemetrexed-Based Regimens in Primary Central Nervous System Lymphoma: A Single-Center Experience Type: Poster Presentation Tarlan Kehtari¹ Raghuram Reddy ¹ Ariel Perez Perez ^{1, 2} Yazmin Odia ^{1, 2} Tiba Alsagheer² Manmeet Ahluwalia ^{1, 2} Zhijian Chen ^{1, 2} George Nahas ^{1, 2} Muni Rubens ² Yuliya Linhares ^{1, 2}
- 36.) The title of the abstract: Concurrent WHO grade II astrocytoma and transformed ALCL in a young female with Crohn's disease: A case report 2025 SNO Pediatric Neuro-Oncology Conference in San Diego
- 37.) **SOHO 2025 Circulating tumor DNA (ctDNA) assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab**

Book Chapters:

1. Hodgkin Lymphoma, 3rd edition of the "Handbook of Hematologic Malignancy" 2024 Co-author with Dr. Ariel Perez Perez
2. Primary CNS Lymphoma, 3rd edition of the "Handbook of Hematologic Malignancy." 2024 Co-author with Dr. Celeste Bello

News Releases

[Community medical centers can safely administer CAR-T, but extensive preparation required \(HEALIO\)](#)

[Outpatient CAR T Therapy Is Safe and Effective in Community Setting | Inside Precision Medicine \(Inside Precision Medicine\)](#)

[Outpatient CAR-T Cancer Therapy Can Be Safe, Effective \(US News\)](#)

[Moving CAR T-Cell Therapy Beyond the Clinic | Blood Cancers Today \(Blood Cancers Today 2025\)](#)

[Outpatient Liso-Cel Administration Shows Favorable Safety in Relapsed/Refractory LBCL - Hematology Advisor \(Hematology Advisor\)](#)

[Outpatient CAR T: Safe, Effective, Accessible | MDedge \(MD Edge\)](#)

[Immunotherapy Services for Cancer | Baptist Health Miami Cancer Institute](#)

[Liso-cel: ASH 2022 Yuliya Linhares Data From the Outreach Study - OncologyTube](#)

[War on Blood Cancers Revolutionizes the Playing Field - BroadcastMed](#)

[Liso-Cel Shows Efficacy in Relapsed/Refractory LBCL - Hematology Advisor](#)

[Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma - MPR](#)

[Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL \(OncLive\)](#)

[DLBCL - CAR T-cell therapy | VuMedi \(2023\)](#)

[World Lymphoma Awareness Day: Novel Therapies Are Paving the Way to Better Patient Outcomes \(Targeted Oncology\)](#)

[Liso-Cel Therapy in the Outpatient Community Setting Demonstrates Durable Response in Patients With R/R Large B-Cell Lymphoma \(Pharmacy Times\)](#)

CLINICAL AND RESEARCH COLLABORATIONS:

Memorial Sloan Kettering- attend MSK weekly Lymphoma Tumor Board, clinical collaboration with lymphoma group including Dr. Grommes, Dr. Torka, Dr. Stuver, Dr. Horwitz and others

University of Miami Malignant Hematology and Stem Cell Transplant group- clinical collaboration with Dr. Lekakis, Dr. Spiegel, Dr. Ramos, Dr. Pongas and Dr. Beitinjaneh and others

BostonGene – Dr. Nathan Fowler, clinical and research collaboration

Moffitt Cancer Center- Dr. Sokolov, co-authoring Hodgkin Lymphoma and Primary CNS Lymphoma book chapters

Moffit Cancer Center- Dr. Zhang Yumeng- collaborative retrospective T-cell lymphoma outcomes protocol

LANGUAGES

English, Spanish, Russian- fluent

Portuguese, French, Ukrainian- conversational, reading comprehension

INTERESTS

Classical music and literature, whole-food plant-based diet recipe development and coaching, travel, yoga and meditation, forest bathing and mushroom foraging, hiking, knitting and crocheting